September/October 2015

Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) is approved for treatment of HIV-1 infection.

The support of specialty pharmacy can facilitate patient access to this new class of drugs for the treatment of high cholesterol.

Policy makers are working to address the needs of patients with Alzheimer's disease.

Approvals for new drugs to treat orphan conditions and asthma are expected.

Several factors must be considered when selecting a supply-chain process.

Due to their infrastructure advantages, health systems are well equipped to take on the challenges of specialty pharmacy.

As payers aim to control costs, they seek better data and reporting on specialty drug use and clinical outcomes.

The particular needs of pharmacists and nurses should be considered by an institution selecting a CSTD system.

Corporate and academic partnerships help prepare new graduates for the world of specialty pharmacy.